3 completed, 2 withdrawn, 1 terminated. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Withdrawn 2, Terminated 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Elpiscience Biopharma, Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors ES014 - Advanced Solid Tumor | Phase 1 | Withdrawn | Elpiscience Biopharma, Ltd. | 2023-04-21 | 2023-01-31 | |
| A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors Part 1 ES002023, Part 2 ES002023 - Advanced Solid Tumor | Phase 1 | Completed | Elpiscience Biopharma, Ltd. | 8 | 2021-12-23 | 2025-05-14 |
| A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors ES102, JS001 - Solid Tumor, Neoplasms | Phase 1 | Completed | Elpiscience Biopharma, Ltd. | 30 | 2021-10-15 | 2025-06-23 |
| A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors ES101 - Thoracic Tumors, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Elpiscience Biopharma, Ltd. | 2021-07-01 | 2022-04-29 | |
| A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors ES102 - Solid Tumors, Neoplasms | Phase 1 | Completed | Elpiscience Biopharma, Ltd. | 18 | 2021-04-01 | 2025-06-23 |
| A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors ES101 - Solid Tumors, Neoplasms | Phase 1 | Terminated | Elpiscience Biopharma, Ltd. | 22 | 2019-06-28 | 2022-04-29 |
Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (1) · Small Cell Lung Carcinoma (1) · Thoracic Neoplasms (1)
toripalimab (1)
China (3) · United States (1)